StockData

Amgen vs Bristol Myers Squibb

AMGN and BMY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMGN and BMY compare

Amgen is the larger company, worth 2.0 times as much as Bristol Myers Squibb ($248B against $125B).

On earnings, Bristol Myers Squibb is cheaper: it trades at 13.6× trailing earnings, against 26.5× for Amgen.

Amgen grew revenue faster over the last twelve months (8.2% versus 4.2% for Bristol Myers Squibb).

Amgen keeps more of each dollar of sales as profit, with a net margin of 24.1% compared with 18.5% at Bristol Myers Squibb.

Both pay dividends: Amgen yields 2.2% and Bristol Myers Squibb 4.1%.

Amgen scores higher on the StockData Score (17 against 14 for Bristol Myers Squibb), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMGNBMY
Size and price
Market cap$248B$125B
Share price$457.93$61.35
Change, 1 year36.0%31.5%
Change, 5 years128%8.5%
Beta (5Y)0.320.11
Employees32K33K
StockData Score
Total score17 (better)14
Valuation score04 (better)
Growth score5 (better)0
Performance score6 (better)3
Health score22
Dividend score45 (better)
Valuation
P/E26.5×13.6× (better)
P/S6.4×2.5× (better)
P/B17.3×5.4× (better)
EV/EBITDA18.8×9.9× (better)
P/FCF25.8×13.5× (better)
PEG4.812.49 (better)
FCF yield3.9%7.4% (better)
Fair value$364.40$87.76
Margin of safety−25.7%30.1% (better)
Growth
Revenue growth (TTM)8.2% (better)4.2%
Revenue growth, 5Y average7.6% (better)2.5%
Net income growth (TTM)34.1%53.1% (better)
EPS growth (TTM)33.3%52.4% (better)
EPS growth, 5Y average2.9%–
Profitability
Gross margin70.9% (better)69.2%
Operating margin32.4%–
Net margin24.1% (better)18.5%
FCF margin24.6% (better)18.6%
Return on equity78.4% (better)44.1%
Return on invested capital19.5%–
Financial health
Debt / equity3.761.83 (better)
Net debt / EBITDA2.671.92 (better)
Interest coverage4.8×–
Current ratio1.481.59 (better)
Altman Z-score2.51 (better)2.20
Piotroski F-score78 (better)
Dividends and buybacks
Dividend yield2.2%4.1% (better)
Payout ratio57.1%55.4%
Years of dividend growth916 (better)
Dividend growth, 5Y average8.0% (better)6.2%
Shareholder yield2.2%4.1% (better)
Ownership
Held by institutions82.7%81.9%
Held by insiders0.21%0.06%
Insider net buying, 12 months−$25.7M−$2.5M (better)
Superinvestors holding–2
Short interest, % of float2.3%2.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.